• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Breakthrough in Cancer Treatment

Raja Aditya by Raja Aditya
3 years ago
in Research & Development, Innovations, Science News
9
Cancer Treatment

Novel, Indigenous, Robust and Affordable Genetically-engineered Chimeric Antigen Receptor T-cell (CAR-T) therapy

IIT Bombay’s Affordable CAR-T Cell Therapy

In a path breaking development in cancer treatment, researchers from the Department of Biosciences and Bioengineering at the Indian Institute of Technology Bombay have developed an indigenous and cost-effective Chimeric Antigen Receptor T-cell (CAR-T) therapy. Led by Rahul Purwar, along with team members Aalia N. Khan and Sweety Asija, this innovation, being displayed and demonstrated in IInvenTive 2024, promises to bring a revolutionary cancer treatment within reach of many, especially in resource-limited settings.

Cancer continues to be a formidable global health challenge, with India alone reporting 1.5 million cases annually. Current cancer treatments often offer only limited extensions to patient life expectancy. CAR-T cell therapy, a novel approach that has shown exceptional efficacy in treating certain types of cancer, was previously out of reach for many due to its exorbitant cost, approximately 400,000 to 500,000 USD per patient.

Addressing this critical gap, the IIT Bombay team has developed a “Make in India” CAR-T platform, significantly reducing the cost of this life-saving treatment. Their work, resulting in the development and patenting of anti-CD19 CAR-T therapy (PCT/IN2019/050111), has demonstrated remarkable anti-tumor efficacy and safety in Phase I/II clinical trials for relapsed/refractory (r/r) B-cell lymphomas and leukemia.

This pioneering work by IIT Bombay has led to the formation of ImmunoACT Pvt Ltd, an IIT Bombay spin-off company. ImmunoACT has recently obtained market authorization for the commercial use of this innovative CAR-T cell therapy, which is anticipated to be available at just a tenth of the cost of existing therapies. This significant reduction in price is expected to make this cutting-edge treatment accessible to a much broader patient population in India and other countries with limited healthcare resources.

The success of this affordable CAR-T cell therapy represents a major milestone in cancer treatment, offering new hope to millions of patients. It not only addresses the financial challenges associated with advanced cancer therapies but also positions India as a leader in biotechnological innovations in healthcare. This achievement underlines the importance of indigenous research and development in transforming healthcare outcomes, especially in countries with high healthcare cost burdens.

For further information on this significant development, Rahul Purwar can be contacted at purwarrahul@iitb.ac.in.

–Raja Aditya

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: anti-CD19 CAR-T therapyCAR-T platformfeaturedIInvenTiv-2024ImmunoACT Pvt LtdIndian Institute of Technology BombayMake in Indiasciencenews
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

Young maize in paired rows on raised beds with water in the furrows between them

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

November 15, 2026 - Updated on November 16, 2026
3
Trays of green and purple microgreens beside a field being sprayed

Small Leaves, Small Particles: Microgreens Have the Evidence. Nano-Urea Is Still Earning It

November 15, 2026 - Updated on November 16, 2026
4

A Crore and a Half Recharge Pits Later: What India’s Water Reforms Can, and Cannot, Teach the Global South

A Purple Broccoli That Seeds in Delhi and a Sponge Gourd That Shrugs Off a Virus

Fourteen Seconds to 241 km/h and Back: What a Runway Test Says About Where Car Performance Now Lives

An Aeroplane on a Helipad: What Electra’s Manhattan Landing Proves, and What It Does Not

After the Space Station: NASA Opens the Contest to Become a Tenant in Orbit

At 94, the Air Force Counts Its Squadrons, and Waits for an Engine India Can Call Its Own

Next Post
Healthcare

A New Era in Healthcare Monitoring

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
8

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist